Heterocyclic compounds as adenosine antagonists
US11028058B2 · kind B2 · utility
2Cited by
21References
52Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 18, 2018 |
| Grant date | Jun 8, 2021 |
| Priority date | — |
| Expiry date | Jul 18, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/14
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.